New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th |
| August 30, 2019 | August 2019 Bond Updates |
|
STOCKHOLM, Aug. 30, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th International Myeloma Workshop (IMW) meeting on September 15, Boston,... |
| View more at: https://www.prnewswire.com:443/news-releases/new-updated-data-will-be-presented-from-oncopeptides-pivotal-phase-2-horizon-study-in-patients-with-extra-medullary-disease-emd-on-september-15th-300909612.html |
| Related News |
|